PHK
EIGR

Point72 Hong Kong’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Point72 Hong Kong’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11
Closed -$3K – 2514
2022
Q1 		$3K Sell
11
-57
-84% -$9.01K ﹤0.01% 1719
2021
Q4 		$11K Buy
+68
New +$13.2K ﹤0.01% 1629
2020
Q2 		– Sell
-83
Closed -$17K – 1492
2020
Q1 		$17K Buy
+83
New +$26.5K 0.01% 591

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Hong Kong's EIGR Position: Q2 2022 in Review

Point72 Hong Kong sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 11 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in EIGR in Q1 2020 and held it in 3 quarters. The position peaked at $17K in Q1 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

  • Point72 Hong Kong reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 11 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $3K.
  • Point72 Hong Kong first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
  • Point72 Hong Kong's Eiger BioPharmaceuticals, Inc. position peaked at $17K in Q1 2020.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.